- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Endomagnetics, the company developing a portfolio of products to improve the standard of breast cancer management, has been named as one of two winners of the inaugural Nanomedicine Award.
The company fended off contenders from around the world - Europe, Australia and the USA - to win the Award. The Nanomedicine Award winners were announced during the Nanomedicine Panel Session at BIO-Europe 2013 in Vienna today.
Launched in June 2013, the Nanomedicine Award has been organised by the European Technology Platform for Nanomedicine (ETPN), together with the EU funded consortium NANOMED2020, to honour the best international nanomedicine innovations. Academia and industry alike were eligible for the first award which covered the fields of diagnostics & imaging, therapeutics and regenerative medicine.
"A global consensus was reached to deliver the award to Endomagnetics for its outstanding development", said a spokesperson for the Award Review Board, which consists of a panel of respected pharma industry specialists. The Board commented on the concrete potential and promise of nanomedicine.
"Endomagnetics is very honoured to have been selected for an inaugural Nanomedicine Award, particularly given the global candidature and great promise of this convergent industry", said CEO of Endomagnetics Dr Eric Mayes. "This award enhances the medtech facet of nanomedicine and increases the visibility of our SentiMag® and Sienna+® system to potential partners as we develop further across the nanomedicine field."
As a winner, Endomagnetics made a presentation at the Nanomedicine Panel Discussion during the awards event. In addition, the company will also present during the CLINAM conference 2014 in Basel, Switzerland.
Last month, Endomagnetics was announced as a finalist in the IET Innovation Awards to be judged on 20th November.
Endomagnetics was founded to solve cancer staging and healthcare challenges through the application of advanced magnetic sensing technology and nanotechnology. Endomagnetics is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston.
The company’s first product, the SentiMag®, is an ultrasensitive hand-held probe for tracking injected Sienna+® nanoscale magnetic materials in the human body. Cambridge, UK-based Endomagnetics is in the process of delivering its technology to global markets. For more information please visit www.endomagnetics.com.
About BIO-Europe 2013
The 19th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,000 global decision makers from biotechnology, pharma and finance, representing upwards of 1,700 companies from over 50 countries, annually attend BIO-Europe in Vienna, Austria to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward.
For more information, please click here
Tel: +44 (0)7923 540695
Dr Eric Mayes, CEO
Tel: +44 (0)1223 652540
Copyright © EndomagneticsIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
SUNY Polytechnic Institute Announces Total of 172 Teams Selected to Compete in Solar in Your Community Challenge: Teams from 40 states, plus Washington, DC, 2 Territories, and 4 American Indian Reservations, Will Deploy Solar in Underserved Communities April 20th, 2017